EMA/344196/2024

European Medicines Agency decision

P/0293/2024

of 16 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (Elucirem), (EMEA-001949-PIP02-18-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0293/2024

of 16 August 2024

on the acceptance of a modification of an agreed paediatric investigation plan for gadopiclenol (Elucirem), (EMEA-001949-PIP02-18-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0145/2019 issued on 17 April 2019, the decision P/0151/2021 issued on 16 April 2021, the decision P/0267/2022 issued on 4 August 2022, the decision P/0143/2023 issued on 21 April 2023 and the decision P/0018/2024 issued on 31 January 2024,

Having regard to the application submitted by Guerbet on 25 March 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for gadopiclenol (Elucirem), solution for injection, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Guerbet, BP 57400, 95943 - Roissy CDG Cedex, France.

EMA/PDCO/140281/2024
Amsterdam, 28 June 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001949-PIP02-18-M05

Scope of the application

Active substance(s):

Gadopiclenol

Invented name and authorisation status:

See Annex II

Condition(s):

Detection and visualisation of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Guerbet

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Guerbet submitted to the European Medicines Agency on 25 March 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0145/2019 issued on 17 April 2019, the decision P/0151/2021 issued on 16 April 2021, the decision P/0267/2022 issued on 4 August 2022, the decision P/0143/2023 issued on 21 April 2023 and the decision P/0018/2024 issued on 31 January 2024.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 29 April 2024.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Detection and visualisation of disorders or lesions with suspected abnormal vascularity in various body regions for diagnostic purposes

2.1.1. Indication(s) targeted by the PIP

Body MRI to detect and visualise lesions and abnormalities within the head and neck, thorax, abdomen, pelvis, and musculoskeletal system

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an additional volume for the solution for injection to avoid risk of overdose *(This study is the same as Study 1 in EMEA-001949-PIP01-16 and subsequent modifications thereof.)*
Non-clinical studies	**Study 2** Dose-range finding toxicity study in rats to determine the toxicity of gadopiclenol in the neonatal and juvenile (pre-post weaning) rats in order to determine appropriate dose levels for the definitive juvenile rat study *(This study is the same as Study 2 in EMEA-001949-PIP01-16 and subsequent modifications thereof.)* **Study 3** Definitive juvenile toxicity study to determine the toxicity of gadopiclenol in the neonatal and juvenile (pre-post weaning) rats *(This study is the same as Study 3 in EMEA-001949-PIP01-16 and subsequent modifications thereof.)*

Clinical studies	**Study 4 (GDX-44-007)** Non-comparative pharmacokinetics, efficacy and safety study in children from 2 to less than 18 years of age presenting central nervous system (CNS) lesions (intracranial, spine and associated tissues), who are scheduled to undergo routine contrast-enhanced MRI of CNS or body *(This study is the same as Study 4 in EMEA-001949-PIP01-16 and subsequent modifications thereof.)* **Study 5** Non-comparative pharmacokinetic, efficacy and safety study in children from birth to less than 2 years of age scheduled to undergo routine contrast-enhanced MRI of CNS or body *(This study is the same as Study 5 in EMEA-001949-PIP01-16 and subsequent modifications thereof.)*
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

Authorised indication(s):

- Elucirem is indicated in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.

It should be used only when diagnostic information is essential and not available with unenhanced MRI.

  - Invented name(s): Elucirem
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Intravenous use
  - Authorised via the centralised procedure